7d3b4d06-1249-4a85-a66a-387d4e2e2cb2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INFLAMMATORY_RESPONSE+0.400
- COMPLEMENT+0.300
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- IL2_STAT5_SIGNALING+0.300
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- DNA_REPAIR-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- GLYCOLYSIS-0.300
- NOTCH_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PROTEIN_SECRETION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- ANGIOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516037 | — | — | 0.885 |
| 2 | ERR2208913 | — | — | 0.867 |
| 3 | ERR2208965 | — | — | 0.837 |
| 4 | s0095135 | — | — | 0.833 |
| 5 | 7ca9c52f-2d6e-4868-b4e8-9dd7937f6b2b | — | — | 0.824 |
| 6 | MDT-AP-2234 | Med | Medulloblastoma | 0.821 |
| 7 | TCGA-A8-A08I-01A-11R-A00Z-07 | — | C | 0.817 |
| 8 | TCGA-AR-A1AW-01A-21R-A12P-07 | — | D | 0.815 |
| 9 | BSR_10_0136_B1_S95 | — | D | 0.814 |
| 10 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |